Inhibition of sympathetic noradrenergic transmission by guanabenz and guanethidine in rat isolated mesenteric artery: Involvement of neuronal potassium channels

Pharmacological Research

Volumn 33, Issue 3, 1996, Pages 171-180

  Fabiani, Maurizio E ^a   Story, David F ^a  

^a RMIT UNIVERSITY   (Australia)

Author keywords

Guanabenz; Guanethidine; Noradrenergic transmission; Potassium channels; Rat mesenteric artery; Transmitter noradrenaline release

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA 2 ADRENERGIC RECEPTOR; AMINE OXIDASE (FLAVIN CONTAINING); APAMIN; DESIPRAMINE; GUANABENZ; GUANETHIDINE; IDAZOXAN; NORADRENALIN; PARGYLINE; POTASSIUM CHANNEL; TRITIUM;

ADRENERGIC TRANSMISSION; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ELECTROSTIMULATION; ENZYME INHIBITION; FEMALE; ISOTOPE LABELING; MALE; MESENTERIC ARTERY; NERVE BLOCK; NERVE ENDING; NONHUMAN; NORADRENALIN RELEASE; PRIORITY JOURNAL; RADIOACTIVITY; RAT; SYMPATHETIC NERVE;

EID: 0030108467     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.1996.0024     Document Type: Article

References (37)

1. 1. Chang CC, Costa E, Brodie BB. Interaction of guanethidine with adrenergic neurons. J Pharmacol Exp Ther 1965; 147: 303-12.
2. 2. Furst CI. The biochemistry of guanethidine. Adv Drug Res 1967; 4: 133-61.
3. 3. Durant GJ, Roe AM, Green AL. The chemistry of guanidines and their actions at adrenergic nerve endings. Prog Med Chem 1970; 7: 124-213.
4. 4. Häusler G, Haefely W. Modification of release by adrenergic neurons blocking agents and agents that alter the action potential. In: ed. Paton DM, The release of catecholamines from adrenergic neurons. Oxford: Pergamon Press, 1979: 185-216.
5. 5. Kirpekar M, Kirpekar SM, Prat JC. Reversal of guanethidine blockade of sympathetic nerve terminals by tetraethylammonium and 4-aminopyridine. Br J Pharmacol 1978; 62: 75-8.
6. 6. Stutzin A, Paravic F, Ormeno G, Orrego F. Guanethidine effects on the guinea pig vas deferens are antagonized by blockers of calcium-activated potassium conductance, apamin, methylene blue and quinine. Mol Pharmacol 1983; 23: 409-16.
7. 7. Habermann E. Apamin. Pharmacol Ther 1984; 25: 255-70.
8. 8. Banks BEC, Brown C, Burgess GM, Burnstock G, Claret M, Cocks TM, Jenkinson DH. Apamin blocks certain neurotransmitter-induced increases in potassium permeability. Nature 1979; 282: 415-7.
9. 9. Maas AJJ, Den Hertog A, Van Der Akker J. The action of apamin on guinea-pig taenia caeci. Eur J Pharmacol 1980; 67: 265-74.
10. + channels. J Physiol 1984; 79: 259-64.
11. 11. Moczydlowski E, Lucchesi K, Ravindran A. An emerging pharmacology of peptide toxins targeted against potassium channels. J Memb Biol 1988; 105: 95-111.
12. 12. McDonald A, McGrath JC. The distribution of adrenoceptors and other drug receptors between the two ends of the rat vas deferens as revealed by selective agonist and antagonists. Br J Pharmacol 1980; 71: 445-58.
13. 13. Sakakibara Y, Muramatsu I, Fujiwara M, Nagasaka Y. Effects of guanabenz on the adrenergic mechanism in rabbit arterial strips. Jpn J Pharmacol 1981; 31: 1029-36.
14. 14. Baum T, Shropshire AT. Inhibition of spontaneous sympathetic nerve activity by the antihypertensive agent Wy-8678. Neuropharmacology 1970; 9: 503-6.
15. 15. Baum T, Shropshire AT. Studies on the centrally mediated hypotensive activity of guanabenz. Eur J Pharmacol 1976; 37: 31-44.
16. 16. Baum T, Shropshire AT, Rowles G, Pelt RV, Fernandez SP, Eckfeld DK, Gluckman MI. General pharmacologic actions of the antihypertensive agent 2,6-dichlorobenzylidene aminoguanidine acetate (Wy-8678). J Pharmacol Exp Ther 1970; 171: 276-87.
17. 17. Bolme P, Corrodi M, Fuxe K. Possible mechanism of the hypotensive action of 2,6-dichlorobenzylidene aminoguanidine: evidence for central noradrenaline receptor stimulation. Eur J Pharmacol 1973; 23: 175-82.
18. 18. Nash DT. Clinical trial with guanabenz: a new antihypertensive agent. J Clin Pharmacol 1973; 13: 416-21.
19. 19. McMahon FG, Ryan JR, Jain AK, Vargas R, Vanov SK. Guanabenz in essential hypertension. Clin Pharmacol Ther 1977; 21: 272-7.
20. 2-adrenoceptors in rat aortic rings. J Pharm Pharmacol 1990; 42: 209-11.
21. 21. Fabiani ME, Story DF. Prejunctional effects of cromakalim, nicorandil and pinacidil on noradrenergic transmission in rat isolated mesenteric artery. J Auton Pharmacol 1994; 14: 87-98.
22. 3H]-noradrenaline. Clin Exp Pharmacol Physiol 1974; 1: 275-89.
23. 3H]-guanethidine and their interaction with adrenergic neurones. J Pharm Pharmacol 1968; 20: 585-94.
24. 24. Mitchell JR, Oates JA. Guanethidine and related agents. I. Mechanism of selective blockade of adrenergic neurons and its antagonism by drugs. J Pharmacol Exp Ther 1970; 172: 100-7.
25. 3H]-(-)-norepinephrine through the deaminated glycol in the rat vas deferens. Biochem Pharmacol 1973; 22: 1147-60.
26. 3H]-noradrenaline in isolated guinea-pig atria. Clin Exp Pharmacol Physiol 1974; 1: 429-39.
27. 27. Langer SZ. Selective metabolic pathway for noradrenaline in the peripheral and in the central nervous system. Med Biol 1974; 52: 372-83.
28. 28. Sarantos-Laska C, Majewski H, McCulloch MW, Rand MJ. Mechanism of noradrenaline release from rabbit atria induced by nicotinic agonists. Arch Int Pharmacodyn Thér 1980; 247: 294-305.
29. 29. Paton DM. Mechanism of efflux of noradrenaline from adrenergic nerves in rabbit atria. Br J Pharmacol 1973; 49: 614-27.
30. 30. Paton DM. Characteristics of uptake of noradrenaline by adrenergic neurones. In: ed. Paton DM, The mechanism of neuronal and extraneuronal transport of catecholamines. New York: Raven Press, 1976: 49-66.
31. 31. Paton DM. Characteristics of efflux of noradrenaline from adrenergic neurones. In: ed. Paton DM, The mechanism of neuronal and extraneuronal transport of catecholamines. New York: Raven Press, 1976: 155-73.
32. 32. Bönisch H. The role of co-transported sodium in the effect of indirectly acting sympathomimetic amines. Naunyn-Schmiedeberg's Arch Pharmacol 1986; 332: 135-41.
33. 33. Bönisch H, Fuchs G, Graefe KH. Sodium-dependence of the saturability of carrier-mediated noradrenaline efflux from noradrenergic neurones in the rat vas deferens. Naunyn-Schmiedeberg's Arch Pharmacol 1986; 332: 131-4.
34. 34. Maxwell RA, Plummer AJ, Scheider F, Povalski H, Daniel AI. Pharmacology of 2-[octahydro-1-azocinyl]-guanidine sulphate (Su-5864). J Pharmacol Exp Ther 1960; 128: 22-9.
35. 35. Cass R, Spriggs TLB. Tissue amine levels and sympathetic blockade after guanethidine and bretylium. Br J Pharmacol 1961; 17: 442-50.
36. 2-adrenoceptors on rat central neurons. Eur J Pharmacol 1985; 105: 265-72.
37. + channel. J Biol Chem 1986; 261: 14607-13.